We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Orencia Patent Appeal Not Moot, Momenta Tells Fed. Circ.

Law360 (November 6, 2018, 4:45 PM EST) -- An infringement case over a Bristol-Myers Squibb Co. patent covering its Orencia biologics product is not moot simply because challenger Momenta Pharmaceuticals Inc. is considering stopping development of a proposed biosimilar,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.